Eli Lilly

San Diego – – October 14, 2026 -- Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total.

About 150 new active substances entered the U.S. oncology market between 2015 and 2024, and launch activity in 2020 to 2024 ran nearly 40% ahead of the prior five years.

Cambridge, Mass. – September 30, 2026 -- Insilico Medicine (HKEX: 3696) has nominated ISM1354, an AI-designed small molecule GIPR antagonist, as a preclinical candidate for obesity, type 2 diabetes and potential cardiovascular applications tied to obesity-associated heart failure.

ISM1354 improves on Insilico's earlier GIPR candidate ISM0676

Las Vegas – – September 16, 2026 -- The obesity therapeutics market across the seven major markets was valued at approximately USD 16 billion in 2025 and is projected to grow at a 27% CAGR through 2036, according to DelveInsight, as a wave of next-generation candidates threatens to disrupt the Eli Lilly-Novo Nordisk duopoly.

Oral GLP-1 Therapies Accelerate Patient Uptake

Novo Nordisk's oral WEGOVY surpassed 5 million cumulative U.S. prescriptions within 30 weeks of launch, while Eli Lilly's oral FOUNDAYO (orforglipron) gained significant traction among patients initiating obesity treatment by mid-2026. Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said FOUNDAYO's once-daily oral formulation positions it for rapid uptake as a more convenient alternative to injectable therapies.

Houston – September 15, 2026 -- Fiber broadband has added an estimated $1.6 billion in aggregate home value to single-family homes sold across Houston since 2020, according to an independent study commissioned by Ezee Fiber titled "Fueling Houston's Growth with Fiber."

Fiber coverage jumped from 75% to 94% of Harris County in three years

Access to fiber broadband providers in Harris County rose from 75% in 2022 to 94% by late 2025, reflecting sustained infrastructure investment across the region. Median download speeds nearly tripled over the same period, climbing from roughly 80 Mbps in December 2022 to more than 280 Mbps by December 2025, approaching the national average of 308.11 Mbps.

Wellesley Hills, Mass. – – September 13, 2026 -- Cure Alzheimer's Fund (CureAlz) has appointed Drs. Michelle Arkin, Ronald B. DeMattos, Donna M. Huryn, and Kalpana Merchant to its Scientific Advisory Board (SAB), adding decades of pharmaceutical drug-discovery experience to the nonprofit's research-funding strategy.

Board addition brings direct experience from an FDA-cleared Alzheimer's drug

Ronald B. DeMattos spent more than 20 years in neuroscience discovery at Eli Lilly, most recently as Senior Vice President and Chief Scientific Officer for Neurobiologics, where he led development of candidates that advanced to clinical studies including donanemab, the FDA-cleared amyloid-lowering antibody marketed as Kisunla for early Alzheimer's disease.

Cambridge, Massachusetts – September 10, 2026 -- Insilico Medicine has published data in Nature Biotechnology showing that its AI-designed idiopathic pulmonary fibrosis (IPF) candidate rentosertib reversed predicted biological age by up to six years in some patients, based on six independently developed proteomic aging clocks.

SHERIDAN, WYOMING - March 13, 2026 - Eli Lilly and Company has reported positive topline results from the Phase 3b TOGETHER-PsO trial, showing that concomitant use of Taltz and Zepbound outperformed Taltz monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. At 36 weeks, the combination met the primary endpoint and all key secondary endpoints, linking deeper skin clearance with clinically meaningful weight reduction in a patient population with high disease burden. For clinicians, payers, and commercial stakeholders in immunology and obesity care, the readout is significant because it supports a more integrated treatment model for patients whose outcomes may be affected by both inflammatory disease and elevated body weight. It also extends Lilly's argument that obesity management may influence psoriasis outcomes in difficult-to-treat populations.